Compare ConocoPhillips (COP) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs CVS Health Corp — how do they compare? ConocoPhillips trades at $133.54 (market cap $155.98B), while CVS Health Corp trades at $86.82 (market cap $112.49B). The key difference: ConocoPhillips is the larger of the two by market cap, and CVS Health Corp pays the higher dividend (3.02%). Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and CVS Health Corp for 83 Days on average.
| COP | CVS | |
|---|---|---|
Market Cap | $155.98B | $112.49B |
Volume | 4,774,951 | 8,467,392 |
Sector | Energy | Health |
52-Week High | $141.22 | $110.60 |
52-Week Low | $85.66 | $70.08 |
Typical Hold Time | 79 Days | 83 Days |
Enterprise Value | $171.58B | $174.83B |
Dividend Yield | 2.59% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $129.84, up 0.38% on the day, with a bullish technical signal driven by moving averages. The stock shows strong profitability with a net income margin of 14.65% and a P/E of 17.17, while recent earnings beat expectations in Q1 and Q2 2026. A 20-year LNG supply deal with Venture Global, announced October 1, 2026, highlights strategic growth initiatives.
The outlook is positive, supported by a 75% analyst buy rating and a consensus price target of $154.75, implying 19% upside. Risks include geopolitical exposure in the Middle East and oil price volatility, but robust cash flow and shareholder returns provide stability for investors.
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
